On Tuesday, Regeneron Pharmaceuticals Inc REGN reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the consensus of $11.29.The company reported sales of $3.79 billion, up 10%, beating the consensus of $3.75 billion.“Regeneron’s financial and commercial strength allows for continued investment in our industry-leading R&D pipeline, while simultaneously returning capital to our shareholders through our newly initiated dividend program and increased share repurchase capacity,” said Leo ...